Joseph Varriale

Clinical Research and Public HealthAIDS/HIVInfectious diseaseVirology Open Access | 10.1172/JCI194081 J Clin Invest. https://doi.org/10.1172/JCI194081. Copyright © 2025, McMyn et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

ResearchIn-Press PreviewAIDS/HIVVirology Open Access | 10.1172/JCI171554 J Clin Invest. https://doi.org/10.1172/JCI171554. Copyright © 2023, McMyn et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. View PDF Abstract HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy (ART).

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy (ART). The reservoir decays slowly over the first seven years of ART (t1/2 = 44 months). However, whether decay continues with long-term ART is unclear. Recent integration site studies indicate gradual selection against inducible, intact proviruses, raising speculation that decades of ART might allow treatment interruption without viral rebound.